BostonGene CEO to Address AI Governance at MWC Barcelona 2026
BostonGene CEO Andrew Feinberg will deliver a main stage keynote at Mobile World Congress Barcelona 2026 on Tuesday, March 3. The announcement highlights BostonGene CEO Andrew Feinberg’s growing influence in global discussions on AI governance and cross-industry innovation.
Mobile World Congress Barcelona is recognized as one of the world’s premier technology gatherings, attracting more than 100,000 industry leaders. Each year, the event explores advancements in artificial intelligence, digital ecosystems, and large-scale innovation. Therefore, Feinberg’s participation signals the increasing importance of responsible AI deployment across sectors.
The Intelligence Dividend: Governing AI at Scale
Titled “The Intelligence Dividend: Governing AI at Scale,” the keynote will examine how artificial intelligence is reshaping industries such as precision oncology, drug development, and global telecommunications infrastructure.
Drawing on his dual leadership roles at BostonGene and Netcracker Technology, Feinberg will discuss why scaling AI requires governance frameworks built on transparency, accountability, and human oversight. In addition, he will outline how lessons from life sciences can guide AI deployment in other high-impact industries.
AI Governance from Oncology to Telecom
According to Surbhi Gupta, Industry Principal at Frost & Sullivan, applying AI in oncology demands exceptional rigor and accountability. As a result, the healthcare sector is helping establish standards that other industries must now adopt.
BostonGene CEO Andrew Feinberg brings a cross-sector perspective, combining AI innovation in tumor and immune biology with large-scale telecom infrastructure experience. Consequently, his keynote will emphasize how disciplined AI governance drives measurable, positive outcomes.
BostonGene’s AI Platform in Precision Oncology
BostonGene develops an AI foundation model that integrates multimodal biological data. This platform supports pharmaceutical research, optimizes clinical trial design, and advances precision oncology programs.
By partnering with global biopharma companies and leading cancer centers, BostonGene continues to demonstrate how AI can improve therapeutic success while reducing development risk. Ultimately, the company’s approach offers a roadmap for scaling artificial intelligence responsibly across industries.
Feinberg’s keynote at Mobile World Congress Barcelona 2026 is expected to reinforce how AI governance frameworks developed in oncology can shape the broader global technology ecosystem.
Read Also: Snowflake Expands Cortex Code CLI to Support dbt and Apache Airflow
